Pharmaceuticals

Methenamine Hippurate Tablets Market Forecast: How Big Will It Be by 2030?

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the methenamine hippurate tablets market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Methenamine Hippurate Tablets Market be in 2030 compared with 2026?

The methenamine hippurate tablets market size has observed substantial growth in recent years. It is projected to expand from $10.11 billion in 2025 to $10.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.4%. The historical growth can be linked to factors such as limited awareness about recurrent UTI prevention, restricted access to specialized urology care, a low adoption rate of antimicrobial tablets, a reliance on hospital-based treatment, and traditional packaging formats.

The methenamine hippurate tablets market is set to experience significant expansion in the coming years, with projections indicating a rise to $14.49 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.5%. This anticipated growth is largely driven by factors such as the increasing occurrence of urinary tract infections, a growing demand for outpatient and homecare treatments, advancements in tablet formulation technology, the rising adoption of personalized medicine, and the expansion of online pharmacy channels. Notable trends expected during the forecast period include a higher prevalence of recurrent UTIs, the growth of the geriatric population, a stronger preference for oral antimicrobial therapies, the broadening of home healthcare services, and the emergence of personalized medication regimens.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9412&type=smp

What Drivers Are Guiding Growth Patterns In The Methenamine Hippurate Tablets Market?

The increasing frequency of urinary tract infections (UTI) is anticipated to stimulate the expansion of the methenamine hippurate tablets market. These common infections arise when bacteria infiltrate the urinary tract, typically via the skin or rectum, reaching the urethra. Methenamine hippurate tablets are utilized to manage or prevent recurrent UTIs caused by specific bacterial strains. For example, data from October 2023, provided by the UK’s National Health Service, revealed 147,285 primary diagnoses of UTIs leading to hospital admissions during the 2022-23 period. A significant portion, 56% (82,392), involved individuals aged 65 and above, with the 80-84 age bracket recording the highest number of admissions at 17,280. Consequently, the rising occurrence of urinary tract infections is a key factor driving the growth of the methenamine hippurate market.

How Is The Methenamine Hippurate Tablets Market Divided Into Segments?

The methenamine hippurate tablets market covered in this report is segmented –

1) By Type: 20 Tablets Or Bottle, 6 Tablets Or Bottle

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

3) By Application: Uncomplicated UTIs, Healthcare-associated UTIs

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By 20 Tablets per Bottle: Standard Packaging, Bulk Packaging Options

2) By 6 Tablets per Bottle: Standard Packaging, Sample Or Trial Packaging

Which Market Trends Are Opening Growth Opportunities In The Methenamine Hippurate Tablets Market?

Major companies active in the methenamine hippurate tablets market are establishing collaborations to enhance their market profitability. A strategic collaboration signifies a deliberate alliance between entities aimed at achieving shared objectives through synchronized efforts, leveraging each other’s strengths and resources. For example, in May 2023, EQL Pharma AB, a Sweden-based pharmaceutical company offering methenamine hippurate tablets, partnered with Dr. Pfleger Arzneimittel GmbH. Through this joint effort, EQL Pharma AB intends to launch Methenamine Hippurate under an EQL-registered brand within the next two years, involving standard license fees, regulatory and reimbursement milestones, and a volume-dependent supply price, pending regulatory approval. Dr. Pfleger Arzneimittel GmbH is a Germany based pharmaceutical company.

Which Major Firms Are Strengthening Their Position In The Methenamine Hippurate Tablets Market?

Major companies operating in the methenamine hippurate tablets market are Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Amneal Pharmaceuticals Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Sandoz International GmbH, Mylan Laboratories Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Methenamine Hippurate Tablets Market?

North America was the largest region in the methenamine hippurate tablets market in 2025. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Methenamine Hippurate Tablets Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9412&type=smp

Browse Through More Reports Similar to the Global Methenamine Hippurate Tablets Market 2026, By The Business Research Company

Methenamine Hippurate Tablets Market Report 2026

https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report

Methicillin Resistant Staphylococcus Aureus Mrsa Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-global-market-report

Muscle Relaxant Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795